TriGemX Bio Goes Public via $246M SPAC Merger

Key Facts

1TriGemX Bio has entered the public market through a merger with a Special Purpose Acquisition Company (SPAC).

2The total proceeds generated from the merger and listing amounted to approximately $246 million.

TriGemX Bio has entered the public market through a merger with a Special Purpose Acquisition Company (SPAC). Investing.com reported that the total proceeds generated from the merger and listing amounted to approximately $246 million.

The company utilized the SPAC route to transition to a public entity and secure capital for its operations and growth. This listing provides the biotech firm with significant liquidity to fund its strategic development and expansion.